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The  Developing  Countries  Vaccine  Manufacturers’  Network  (DCVMN)  brought  together  nearly  220 senior
representatives  of  governmental  and  non-governmental  global  health  organizations,  as  well as  corpo-
rate executives  of  emerging  vaccine  manufacturers,  from  26 countries  for a two-day  tailored  lectures,
Q&A  sessions,  CEOs  panel  discussion  and  networking  opportunities,  followed  by  a vaccine-technology
symposium  and  visit  to manufacturing  facilities  in Hanoi,  Vietnam.  Participants  included  representatives
of  38  vaccine  manufacturers,  as  well  as international  partners  and  collaborating  research  institutions,
with  39% female  participants.  The  Vice-Minister  of  Health  to Vietnam  commended  the speakers  and
participants  to this  Annual  General  Meeting,  devoted  to achieve  our  common  goal  of protecting  peo-
ple  against  infectious  diseases  with  better  vaccines,  for a healthier  life. He  reminded  the  audience  that
the  ﬁrst  vaccine  produced  in  Vietnam  was  oral  polio  vaccine  (OPV)  in  the  early  1960s  and  contributed
to  polio  eradication  in Vietnam,  in  2000.  Through  its manufacturing  resources,  Vietnam  eliminated
neonatal  tetanus  in  2005,  and  has  controlled  measles  and  hepatitis  B spread.  The Ministry  of  Health
hopes  that  by sharing  experiences,  delegates  at this  conference  will foster  international  cooperation
and  partnerships  among  organizations.  CEOs  elaborated  on challenges  and  opportunities  for  emerging
countries.. Introduction
The conference was opened by DCVMN President, M.  Suhardono,
y acknowledging Vabiotech, the host of this event, and the govern-
ent of Vietnam, for their engagement in vaccine manufacturing
nd for their hospitality towards the international members and
takeholders. The Honourable Vice-Minister of Health of Vietnam,
r.  Nguyen Thanh Long, stated that the Vietnamese Government
nd the Ministry of Health strongly support the vaccine manufac-
uring system in the country. Over the past 25 years, the National
xpanded Programme on Immunization has achieved signiﬁcant
esults by changing disease patterns in children. There are now
our major vaccine manufacturers in Vietnam, namely VABIOTECH,
OLYVAC, DAVAC, and IVAC. The local manufacturers supply so far
en out of eleven vaccines for the National Expanded Programme on
mmunization in Vietnam including the licensed oral polio vaccine,
TP, BCG, Japanese encephalitis, hepatitis B, cholera, typhoid fever
nd measles vaccines. The vaccine manufacturers in Vietnam count
any new vaccines under evaluation or licensure such as rotavirus,
/H5N1 inﬂuenza, seasonal inﬂuenza, dengue, and combination
accines.
 Important note: This report summarizes the views of experts as presented at
n international scientiﬁc conference in a given time point and context, and does
ot  necessarily represent the decisions or the stated policy of any institution or
orporation.
ttp://dx.doi.org/10.1016/j.vaccine.2014.05.075
264-410X/2. Global public health needs and challenges
B. Aylward, from WHO, gave a key note lecture focusing on
the Global Polio Eradication strategy. Since the Polio Eradication
programme started, in 1988, the number of polio-paralyzed chil-
dren has decreased tremendously, from an estimated over 350,000
children paralyzed every year to a few hundreds in 2013, due to
vaccination, and poliovirus type 2 has been eradicated, in 1999.
However, between 2000 and 2011, 14 countries reported circu-
lating vaccine-derived (type 2) poliovirus outbreaks. While India
stopped transmission in 2011, cases were alarmingly increasing in
Nigeria, Afghanistan and Pakistan during the same period. Thus on
25th May  2012 the World Health Assembly declared polio erad-
ication an emergency for global public health and urged WHO
to rapidly ﬁnalize a Polio Endgame Strategy. A key element of
the endgame is the removal of the type 2 component of the oral
poliovirus vaccine, facilitated by the introduction of an afford-
able inactivated injectable polio vaccine (IPV) globally. A study
conducted in Cuba reported a breakthrough in the search for an
‘affordable IPV’ with one ﬁfth dose of IPV found to achieve 63%
seroconversion, and 99% priming against poliovirus type 2 [1]. This
result was  crucial to a landmark SAGE recommendation that all
countries should introduce at least one dose of IPV into their rou-
tine immunization programmes to mitigate the risks associated
with withdrawal of OPV2. To date in 2013, no type 3 polio virus
cases have been detected for the ﬁrst time in history, and there has
been a nearly 50% decrease in endemic virus cases in Afghanistan,
Nigeria and Pakistan. Still reports of spreading of viruses to Egypt,
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srael, and Somalia are of concern and are challenging eradication
esources.
The Polio endgame goal is to complete eradication and con-
ainment of all wild and vaccine derived polio viruses, with a
lobal plan that has four objectives [2], the second of which is par-
icularly important for vaccine manufacturers: OPV2 withdrawal
nd IPV introduction in 125 countries within 24 months. New
artners are helping with both interruption of wild poliovirus
ransmission and implementation of the new endgame strategy,
ith the Red Cross/Red Croissant movement and GAVI being par-
icularly important examples. 14 countries, representing 61% of
he OPV-using population in the world are the priority for IPV
ntroduction. In the near future the eradication effort will also
eed a robust supply of monovalent OPV type 1, bivalent OPV
ype 1&3, and trivalent OPV; bivalent OPV needs to be licensed for
outine use as part of the strategy for removing OPV2, and OPV
ype 2 withdrawal is planned for as early as 2016. The world still
eeds new low cost IPV formulations and new devices to improve
mmunization.
T. Mundel provided a key note lecture on the importance of
ndustry partnerships and delivery focused innovation in global
ealth, as well as an update on the Bill and Melinda Gates Foun-
ation (BMGF) evolving strategies around its three major areas
f focus programmes: global health, global development, and
nited States programmes. The Foundation’s mission is to dis-
ribute funds most efﬁcaciously, with a 2012 budget of 3.4 billion
ollars dedicated to over 1200 programme related investments
rants, including 600 million dedicated to R&D and 400 million
o delivery projects. Over the last decade the number of manufac-
urers supplying vaccines for the poorest GAVI funded countries
oubled with DCVMs participation, and today two thirds of chil-
ren worldwide get vaccines from DCVMs. A 36% drop in cost to
ully immunize a child with Pentavalent (DTPHepB-Hib), Pneu-
ococcal conjugate vaccines (PCV), and rotavirus vaccines (from
5 to 22 USD) has been realized over the last decade. Mortal-
ty of children under 5 years old decreased from 20 million in
960 to about 7 million in 2012. Neonatal and nutritional disor-
ers have decreased in the Americas but still not in Africa and
sia.
Thus, Dr. Mundel emphasized that partnerships are impor-
ant and innovation in vaccine ﬁnancing is critical and is also
nabling to save more lives. “Programme Related Investments”
PRIs) are increasing in scope and size. As an example, a new
lobal Health Investment Fund of 100.000 million dollars was
aunched in 2013 primarily for the purpose of providing funds
or late stage clinical trials, and is open to industry, individ-
al and institutional investors. The foundation’s PRI programmes
re focused on the development of drugs, vaccines, diagnostics,
nd other interventions for low-income countries. It includes
ut is not limited to fund investments, equity investments,
oans and guaranties. An example of innovative global part-
ership to end deadly meningitis type A epidemics in Africa
s illustrated by the development and low cost per dose of
 meningitis A vaccine. A two-pronged introduction strategy
ncluded mass campaign vaccinations to gain immediate bene-
ts, and vaccine integration into routine childhood immunization
rogrammes, with over 100 million people immunized since
010. He said that the Foundation is committed to enabling
trong partnerships for innovations in vaccine development
ith DCVMs, to support new candidate vaccines, such as new
onjugation technologies, new adjuvants technologies, process
evelopment technologies, and to facilitate the provision of scien-
iﬁc, technical, and regulatory advice to manufacturers to minimize
egulatory delay and speed access to needed products, and improv-
ng incentives for the Prequaliﬁcation (PQ) process for critical
accines.32 (2014) 6325–6329
3. Global vaccines procurement and supply
M.  Shirey gave an update on UNICEF supply division activities
related to vaccines. UNICEF procures vaccines and immunization
supplies on behalf of around 100 countries annually and 1.89 bil-
lion vaccine doses were delivered through 1946 shipments in 2012,
including 0.78 billion doses procured from DCVMs with a value
of US$338 million (32% of total value of US$ 1, 053 million). The
majority of the value of procured vaccines reﬂect PCV (ca. 40%), Pen-
tavalent (ca. 30%) and OPV (ca. 15%) [3]. UNICEF’s procurement is
aimed at achieving Vaccine Security – the sustained, uninterrupted
supply of affordable vaccines of assured quality.
UNICEF requests for proposals include multi-year tender and
award period providing planning horizon and more certainty to
manufacturers. Awards and Long Term Agreements are based in
‘good faith’ framework agreements, and on accurate forecasts, but
treated as contracts. To achieve exceptional results exceptional
contracts have been awarded, such as ﬁrm or pre-paid vaccines,
when a funding partner has agreed. Generally, multiple suppliers
are awarded per product and pipeline is assessed in award recom-
mendation, to incentivize continued market development.
For instance, OPV supply is going to be extremely tight
through to mid-2014, and UNICEF has contracts in place
for 2013–2016/2017, while conducting a multi-year tender
(2014–2017/2018) to secure sufﬁcient supply of IPV to meet the
Polio Endgame timelines, and achieve affordable pricing. An IPV
tender was issued on 4 October that includes a sub-set of 124 OPV-
using countries and up to 404 million doses requested.
For Pentavalent, there are expectations of 180 million doses
supplied annually, fully awarded for 2013–2014, with some quan-
tities not awarded for 2015–2016, as other demand for Middle
Income Countries (MICs) (annual tender) and expansion in India
are expected.
Regarding PCV, a third call for offer was  concluded on July
2013, securing 50 million doses annually, increasing total supply
to 146 million doses from 2016 onwards. There are still 405 mil-
lion dollars out of $1.5 billion of Advance Market Commitment
(AMC) funds available for future awards to contribute to the AMC
objective of creating a healthy vaccine market including multiple
manufacturers. Thus manufacturers with pneumococcal vaccines
in development should register to the AMC  to have supply offers
assessed, if supply is envisaged within 5 years.
There is a need to rapidly expand the supply base of prequaliﬁed
rotavirus vaccines to continue accelerate introductions and to meet
projected future demand. UNICEF tendered for 88 million courses of
rotavirus vaccines for the period 2012–2016, and 71 million courses
have been awarded to two suppliers with prequaliﬁed vaccines
while additional awards are to be made based on available supply
and new country demand. Rotavirus vaccine demand is higher than
supply (29 countries approved with GAVI support with 10 coun-
try introductions, procuring through UNICEF) with 90% of demand
for one vaccine using a two  dose schedule, resulting into scaling
up of supply while requiring countries to delay introductions, and
reduced vaccination cost per course. Human Papillomavirus (HPV)
vaccine demand from GAVI 56 countries may  reach 39 million doses
by 2020, and ﬁrst tender was  awarded in 2013 to cover 10 demon-
stration programmes and 1 national introduction. Peak demand for
Measles-Rubella (MR) is forecasted to occur in 2017–2018, but will
depend on actual country plans, if delayed Measles demand will
increase.
UNICEF is experiencing an increase in countries requiring
national licensure. The National Regulatory Authorities (NRA)
of importing country need to undertake an oversight role. An
increasing number of countries also accept WHO  Procedure for
Expedited Review of Imported Prequaliﬁed Vaccines for Use in
National Immunization Programmes. [4] UNICEF is working with
ccine 32 (2014) 6325–6329 6327
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Fig. 1. Chart depicting the costs in millions US dollars (left scale) and percentage
of  the expanded programme on immunization (EPI) funded by national budgets (in
percentage) from the 1990s until 2010, and the number of countries with immu-
nization laws (right scale), among the 48 countries or territories in the American
continent. The immunization programmes in the Americas are recognized as suc-
cessful for eliminating infectious diseases and achieving high vaccination coverage,
but also on achieving ﬁnancial sustainability and having a high political commit-
ment. Even with an increase in immunization costs over the years, particularly in
2007–2008, national budgets increased their participation to reach 99% in 2010. In
2012, 27 of the 48 countries/territories had immunization laws available that declare
vaccination as a public good, free of charge to the population, secure budgets and
deﬁne the procurement mechanisms for vaccines.Conference report / Va
overnments, donors, and suppliers to support MICs purchase of
ffordable vaccines, particularly for HPV, Rotavirus and Pneumo-
occal vaccines, based on indicative interest from 24 MICs. In
ddition, separate annual tender for Pentavalent vaccines, as well
s demand for IPV is included in tenders for MICs. [5]
D. Rodrigues provided an update on the Revolving Fund of
he Pan American Health Organization (PAHO) for the procure-
ent of vaccines for the region of the Americas. This is the
eading region for elimination and eradication of infectious dis-
ases, notably of polio, measles and more recently rubella. New
accines have traditionally been rapidly and largely introduced
n American countries, for instance with 90% of the birth cohort
n the Region is in countries that include the pneumococcal vac-
ine in its regular programme (60% of the cohort of LAC1), 87%
f cohort is living in countries that already use rotavirus vac-
ine (60% of the cohort of LAC) and 58% of girls 10–14 years old
ive in countries that have the HPV vaccine. Four components
ay  have contributed to this regional success: (a) vaccines are
eclared as public good, (b) there is commitment and solidarity to
chieve regional goals, (c) continuous availability of high-quality
accines, through the Revolving Fund, and (d) vaccination is highly
ccepted by populations in Latin America. In the region of the
mericas, more than 95% of the funds used to cover the oper-
ting expenses of the immunization programmes, including the
rocurement of vaccines, are funded with national budgets. Also
he majority of countries already have immunization laws in place
Fig. 1).
To date 15 vaccines are recommended to be included in the
ational immunization programmes in the Americas2. For exam-
le, inﬂuenza vaccines had greatest uptake in this region of the
orld with 40 countries adopting seasonal vaccination, with major-
ty for elderly, health workers and persons with chronic diseases,
nd approximately half of the countries offering vaccination to
regnant women  and children. The PAHO Revolving Fund repre-
ents for manufacturers a “single window” to access 40 countries,
 vaccine market with sustainable demand, prompt payment, post
arketing surveillance, among other features. Also 60 days credit
ine to countries supports promptly placement of purchase orders.
resently there are needs for yellow fever supply, varicella and
TaP. Also the Region represents an opportunity for increasing
ompetition for seasonal inﬂuenza, PCV, Rotavirus, and HPV vac-
ines.
M. Malhame presented the GAVI Alliance Vaccine Investment
trategy update, which is the mechanism to make decisions for
upport to introduction of vaccines in the poor countries ﬁnanced
y GAVI. In 2008 the GAVI board asked for a comprehensive pro-
ess, instead of case-studies, as in the previous years to deﬁne
he funding portfolio. Based on analytical data, including demand
orecast, and technical and country consultations, surveys and
nterviews with stakeholders along the last 12 months, 15 vac-
ines were reviewed according to demand, cost, impact and other
eatures. Five vaccines were prioritized: malaria and maternal
nﬂuenza based on to public health impact, cholera and yellow
ever based on epidemic potential, and rabies based on cost-
ffectiveness (cost per death averted). The prioritized vaccines
ere discussed at the board meeting on November 21st, and two
accines were selected: malaria, cholera stockpile and additional
ellow fever campaigns. GAVI will reevaluate the vaccine landscape
n 2018.
The speakers, moderated by K. Bush and M.  Datla, discussed the
hallenges of global vaccines’ procurement. K. Bush acknowledged
1 Latin America & The Caribbean (LAC).
2 BGC, DTP, Hib, HepB, Polio MMR,  Yellow Fever, Inﬂuenza, PCV, Rota, HPV,
neumo23, HepA, varicella and meningitis.Courtesy of D. Rodrigues.
the DCVM group for commitment and investments in vaccines
manufacturing, and mentioned that the BMGF works through
partnerships: there is no purchase, no storage, but help through
not-for-proﬁt partners. He explained that the life sciences group at
the Foundation focuses on industry partnerships for a deeper and
broader engagement and understand the industry capabilities and
sustainability of goals. The group has dedicated resources for work-
ing with multinationals, biotech, and DCVMs that have different
operating models and expectations. Another group working with
vaccine policy groups supports the interface between supply and
demand. He added that criteria to select industry partners include:
(1) corporate business strategy overlapping programmatic needs
of EPI vaccines; (2) availability of a technology platform to operate
supply such as GMP  compliance and a culture of continuous qual-
ity improvement; (3) access to know-how and scale-up expertise
as well as innovation to match affordability; (4) history of ﬁnan-
cial sustainability; (5) programmatic demand knowledge to run a
sustainable business; (6) equity in biotech industry. Still the Foun-
dation has the ﬂexibility and ability to be creative and welcomes
innovative proposals.
D. Rodriguez added that the PAHO Revolving Fund is now
focusing on vaccine affordability rather than on security, and thus
agreements are on an annual or biannual basis, rather than long-
term multiyear agreements like UNICEF. The large majority of
member States in the Americas use their own funds to acquire
vaccines, and pool procurement is based on solidarity with small
countries that would not have access to good deals if out of the
pool. M.  Malhame added that GAVI engages with manufacturers
and donors through an open dialogue on potential demand, includ-
ing the industry in the discussions of forecast and roadmaps for
vaccine introduction. Limited vaccine supply is often a challenge,
meant D. Rodrigues, such as presently Yellow Fever (YF) vaccine
supply shortage. Despite four YF manufacturers the demand is not
met, due to cumbersome technology and the lack of incentives to
larger volumes’ supply, despite some signal of expanded campaigns
to come. Another challenge is an imbalance created by increased
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entavalent demand in some countries that could result in shortage
f DTP for other countries.
A concern to manufacturers of developing countries is the
ncreasing requirements for registration in individual countries,
elaying access, even when vaccines have gone through pre-
ualiﬁcation, while the tools and instruments exist to expedite
egistration.
. Pathways for access to vaccines
P. Duclos presented WHO’s Strategic Advisory Group of Experts
SAGE) on immunization, which issues global policy recommen-
ations and strategies to supporting regional/national challenges.
AGE recommendations have an impact on countries’ vaccina-
ion policies, global partnerships, regulatory processes, vaccine
emand and vaccine supply by industry. The technical advisory
ommittees and working groups provide evidence to inform the
lobal policy recommendations and strategies of SAGE that can
e adapted and implemented, within the local epidemiological
nd socio-economic context, at regional and national levels. SAGE
orking groups, composed by SAGE members and additional inde-
endent experts, are established to review evidence and address
peciﬁc issues in great depth and prepare for fruitful discuss-
ons at plenary SAGE meetings. Issues taken into consideration
y SAGE include disease epidemiology, vaccine characteristics,
linical and immunization features and economic considerations.
dditionally, health system opportunities and other existing inter-
entions and control strategies, social impact, legal and ethical
ssues are also considered. However, information on alternative
mmunization schedules, vaccines co-administration, risk groups
r (post-marketing) surveillance data is often lacking to support
ecision making. The WHO  vaccine position papers, available in
nglish, French, Arabic, Chinese, Russian and Spanish, summa-
ize the recommendations of SAGE and serve as key reference
ocuments. [6] Comments from vaccine manufacturers to the posi-
ion papers are sought through e-consultations, while aware of
otential conﬂicts of interest and equity. SAGE has also provided
uidance to vaccination in humanitarian emergencies, based on
ssessment of the epidemiological risk, vaccine characteristics,
nd prioritization in the context of other urgent public health
eeds and security, ﬁnancial, and political realities. New SAGE
orking groups will be formed to review evidence leading to
pdating recommendations on the use of Japanese encephalitis,
ertussis, varicella, hepatitis E, and malaria vaccines among oth-
rs.
N. Dellepiane gave updated information on WHO  Prequaliﬁca-
ion (PQ) procedures, focusing on the strategic priorities, including
ecuring the supply base for priority vaccines for developing
ountries, facilitating access to quality products, improving efﬁ-
iency of the prequaliﬁcation procedure and to expanding portfolio
or vaccine introduction. Related activities were conducted includ-
ng the amendment of several WHO  guidance documents [7–15],
he implementation of expedited/facilitated registration procedure
or prequaliﬁed vaccines in receiving countries, and two WHO
orkshops in China and India targeting at manufacturers with
otential for PQ of priority vaccines. In 2013, an Internet based tool
as been developed and hosted on WHO-server for online submis-
ion, processing and monitoring of registration applications.
She introduced the features of the revised procedure, notably,
he Programmatic Suitability of Product Characteristics (PSPQ)
ommittee, the streamlined prequaliﬁcation procedure of 6 months
or manufacturers in countries with eligible authorities, and the
stablishment of annual reporting systems (PQVARs). Finally,
 customers’ survey was made of PQ service design (PQ pro-
ess) and service delivery. Still, there are concerns about overall32 (2014) 6325–6329
time required for prequaliﬁcation and process time inefﬁciencies
(e.g. overall elapsed time, knowing when to expect a response).
Manufacturers would like to see samples tested in parallel to the
review of the ﬁle, while this may  not be feasible to implement. In
addition, there is a need for harmonization of expectations between
different GMP  auditors, categorization of deviations and of GMP
code applied.
5. Panel discussion of Chief Executive Ofﬁcers
This year the ﬁrst open Chief Executive Ofﬁcers (CEOs) Panel
Discussion held at an annual general meeting was  moderated by H.
Dabas, from the Clinton Health Access Initiative (CHAI). CEOs from
9 DCVMN member companies discussed how to turning challenges
into opportunities.
A. Homma  from Biomanguinhos (Brazil) shared the success
experiences in technology transfer from large multinationals
to Brazilian manufacturers. He noted that the support from
government is very important to facilitate negotiations with
multinationals. The public immunization policy, the population
acceptance and the market size are also components of success.
A. Homma  encouraged DCVMN members to intensify discussions
and build up closer cooperation and technology transfer initiatives
among Network members, which will leverage investments and
better prepare emerging manufacturers to meet the supply chal-
lenges of developing countries.
C. Campa from Finlay (Cuba) noted that the ﬁve conditions for
Finlay to turn challenges into opportunities included: the support
from the local government, the high qualiﬁed human resources, the
cooperation with other institutions inside and outside the country,
conﬁdence and loyalty to the solidarity principles of vaccination
programmes across national borders, and existence of a robust sys-
tem to carry out clinical trials.
S. Gao from Innovax (China) noted that the vaccine manufac-
turing quality management system is crucial to achieve WHO  PQ,
rather than the technology itself. He highlighted the recombinant
vaccines based on a new E. coli expression system as an efﬁcient
vaccine technology platform. In addition to Hepatitis E, a new HPV
vaccine has been developed based on the expression system. He
emphasized that products with high cost-effectiveness will be very
important for expanding immunization in developing countries.
Finally, he expressed his interest in cooperation with other DCVMN
members for technology transfer or development.
K. Ella, from Bharat Biotech (India) shared his vision on new
vaccines’ development. The attention to the speciﬁc health needs of
the country and the strong will to be part of a solution to saving the
lives of children are the key to succeed. With support from donors
vaccine companies still have to face the challenge of how to keep
the quality while keep affordable prices.
As illustrated by D. Dat, from Vabiotech (Vietnam), the manufac-
turers in Vietnam have been working closely with the government
since the 1950s to eradicate polio and protect people from other
infectious disease. However, applying for WHO  PQ is a challenge
that keeps the products of Vabiotech away from other populations
in the world. Thus the company cooperated with other companies
through technology transfer, for cholera vaccines for example, to
make the product available globally.
M. Datla from Biological E (India) considers quality issues as
daily business and great opportunities to introspect and improve
the quality management system. She noted that the management of
suppliers is also crucial to ensure the quality of ﬁnal products. As for
the partnership with international organizations such as GAVI, M.
Datla noted that transparency in relationship and enough patience
are very important approaches, especially to recognize the tangible
added value of the partners.
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M.  Makhoana from Biovac (South Africa) highlighted challenges
or vaccine manufacturers in Africa, such as the lack of resources
nd specialized workforce. The company has to assess the epi-
emiologic data and balance the costs. In Africa, opinion leaders
upport vaccine manufacturers, and investors can expect the eco-
omic improvement in the future.
A. Muktadir from Incepta (Bangladesh), shared the story of how
e started the business and illustrated the biggest challenges. One
hallenge comes from the PQ barrier because the local NRA is not
onsidered fully functional. The simple motivation is to develop
igh quality vaccines for those people who need them. Dr. Muktadir
xpressed appreciation for the platform provided by DCVMN and
xpressed his interest in seeking partners for vaccine technology
ransfer to Bangladesh.
A. Poonawalla from Serum Institute of India, shared his success-
ul business experience, and noted that patience and continuous
nvestment are very important while fostering cooperation with
nternational organizations, particularly to achieve PQ. Challenges
uch as to integrate the manufacturers, the donors and the NGOs
nto one common philosophy do exist. He gave two suggestions to
CVMN members: to establish strong R&D and quality systems and
o register the products in as many countries as possible.
All CEOs agreed that DCVMN created a remarkable and vibrant
latform to share knowledge and communicate solutions to emerg-
ng issues. It was concluded that entrepreneurial thinking is
mportant to make changes happen and the Network community
s serving a society where access to preventive vaccination will be
ully met  everywhere to assure supply of needed vaccines for future
enerations.
onﬂict of interest
The authors are employees of the respective indicated orga-
izations, and have no conﬂict of interest to declare. DCVMN
nternational did not provide any ﬁnancial support to speakers or
oderators to participate at this meeting.
cknowledgements
We  are grateful to all speakers and moderators, whose gracious
articipation and contributions made the conference possible. We
re indebted to the US Human and Health Services (HHS) Depart-
ent for the in-kind support of the registration website. We are
rateful to the local organizing committee and to all volunteers
ho helped preparing and during the conference, especially Ms.
an Huong for coordination of many logistic aspects of the confer-
nce. We  thank Vabiotech and corporate partners for supporting
CVMN educational activities in 2013 with grants:Polyvac, Merck
illipore, Temptime, Bioengeneering, SGS, Alfa Wassermann, GEA,
osch. This conference was partly supported by a grant of the Bill
nd Melinda Gates Foundation, Grant no. OPP1097005.
ppendix A.
Mahendra Suhardono (Biofarma, Indonesia), Akira Homma
Biomanguinhos, Brazil), Gutla V.J.A. Harshavardhan (Bharat
iotech, India), Morena Makhoana (Biovac, S.Africa), Mahima Datla
Biological E, India), Luciana Leite (Butantan, Brazil), Suresh Jadhav
Serum Institute of India), Yonglin Wu (CNBG, China), Yongzhong
ao (Innovax, China).eferences
[1] Resik S, Tejeda A, Sutter RW,  Diaz M,  Sarmiento L, Aleman˜i N, et al. Prim-
ing  after a fractional dose of inactivated poliovirus vaccine. N Engl J Med
2013;368(January (5)):416–24, http://dx.doi.org/10.1056/NEJMoa1202541.32 (2014) 6325–6329 6329
[2] WHO, Rotary, CDC, UNICEF. Polio eradication & endgame, strategic plan
2013–2018, edition; 2013. Available from http://www.polioeradication.org/
Portals/0/Document/Resources/StrategyWork/PEESP EN US.pdf
[3] UNICEF. Procurement advancements. In: Presentation to DCVMN Annual
General Meeting, Hanoi October. 2013. Available from http://www.unicef.
org/supply/ﬁles/2013 10 07 UNICEF DCVMN Presentation Final.pdf
[4] WHO  procedure for expedited review of imported prequaliﬁed vaccines
for use in national immunization programmes; 2007. Available from
http://whqlibdoc.who.int/hq/2007/WHO IVB 07.08 eng.pdf
[5] For additional information on UNICEF’s MIC  new vaccine procurement initia-
tive, Available from http://www.unicef.org/supply/index 67101.html
[6] WHO  position papers on vaccines, Available from http://www.who.int/
immunization/documents/positionpapers/en/
[7] WHO  guideline for the preparation of the product summary ﬁle for
vaccine prequaliﬁcation; 2006. Available from http://whqlibdoc.who.int/
hq/2006/WHO IVB 06.16 eng.pdf
[8] WHO  clinical considerations for evaluation of vaccines for prequaliﬁcation:
points to consider for manufacturers of human vaccines; 2010. Available
from http://www.who.int/immunization standards/vaccine quality/clinical
considerations oct10.pdf
[9] WHO  Assessing the programmatic suitability of vaccine candidates for
WHO  prequaliﬁcation; 2012. Available from http://apps.who.int/iris/
bitstream/10665/76537/1/WHO IVB 12.10 eng.pdf
10] WHO  guide to master formula; 2011. Available from http://www.who.int/
immunization standards/vaccine quality/guide to master formulae ﬁnal
2012.pdf
11] WHO  environmental monitoring of clean rooms in vaccine manufacturing
facilities; 2012. Available from http://www.who.int/immunization standards/
vaccine quality/env monitoring cleanrooms ﬁnal.pdf
12] Priority setting for WHO  vaccines prequaliﬁcation programme for
2014–2015, Available from http://www.who.int/immunization standards/
vaccine quality/pq priorities/en/
13] Guidance on variations to prequaliﬁed vaccines, Available from http://www.
who.int/immunization standards/vaccine quality/variations pq vaccine/en/
index.html
14] WHO  draft guidance on reporting variations to a prequaliﬁed vac-
cine; 2013, Available from http://www.who.int/immunization standards/
vaccine quality/variations 1st draft public comments 21feb2013.pdf
15] WHO  guide on deviations handling and quality risk management: a note for
guidance for the manufacture of prequaliﬁed vaccines for supply to United
Nations agencies; 2013. Available from http://www.who.int/immunization
standards/vaccine quality/risk july 2013.pdf
Sonia Pagliusi a,∗
Rahman Rustanb
Weidan Huangc
Thuvan Nguyend, DCVMN Executive
Committee1
a DCVMN International, Chemin du Canal 5, Nyon
1260, Switzerland
b PT. Biofarma, Jl. Pasteur No. 28, Bandung 40181,
Indonesia
c Xiamen Innovax Biotech Co., Ltd., No. 130 XinYuan
Road, Haicang District, Xiamen, Fujian 361022, China
d Vabiotech, Yersin Street, Hanoi, Viet Nam
Corresponding author. Tel.: +41 791245544;
fax: +41 22 3628211.
E-mail addresses: s.pagliusi@dcvmn.org
(S. Pagliusi), Rahman.rustan@biofarma.co.id
(R. Rustan), weidan huang@innovax.cn
(W.  Huang), thuvan@vabiotech.com.vn
(T. Nguyen).
1 See Appendix A for collaboration details.
11 February 2014Available online 9 June 2014
